Loading organizations...
§ Private Profile · Cambridge, MA, USA
Totient is a technology company.
Totient is an AI-driven biotechnology company focused on the discovery of novel tissue-specific antigens. It leverages tertiary lymphoid structures (TLSs) and reconstructs antibodies from patients exhibiting exceptional immune responses. Through this unique approach, the company builds a comprehensive library of human-derived antibodies, which serve as foundational tools for developing next-generation cell therapies and various other therapeutic modalities.
The company was co-founded by Deniz Kural, PhD, and James Sietstra. Their foundational insight stemmed from recognizing the immense, untapped potential within the human immune system, specifically in individuals displaying powerful immune responses. Totient was established to systematically harness these advanced natural mechanisms for the identification and development of highly specific antibodies, thereby advancing beyond conventional discovery techniques.
Totient’s product primarily benefits the development of advanced cell therapies and other precision therapeutic approaches. The company envisions a future where its extensive library of human-derived antibodies and advanced discovery platform unlocks entirely new avenues for targeted treatments, leading to more effective and personalized medicines. Its ongoing work continues to contribute to the broader mission of accelerating drug discovery for complex diseases.
Totient has raised $10.0M across 1 funding round.
Totient has raised $10.0M in total across 1 funding round.
Totient has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2020 | $10M Seed | — | Jonathan Milner, Kaitai Capital, Steven Tregay, Sands Capital, TAU Ventures, Viva Biotech | Announced |
Totient has raised $10.0M in total across 1 funding round.
Totient's investors include Jonathan Milner, Kaitai Capital, Steven Tregay, Sands Capital, Tau Ventures, Viva Biotech.
Totient was an AI-driven biotechnology company that developed a platform leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and create high-affinity antibodies targeting them.[1][2] It served biotech researchers and drug developers by addressing the challenge of discovering precise, tissue-specific targets for therapies, particularly in areas like oncology and infectious diseases, with early focus on a novel COVID-19 program.[1] The company emerged from stealth in 2021 with $10 million in seed funding, demonstrating initial momentum in AI-powered drug discovery, though it appears to have ceased operations based on past-tense descriptions in recent records.[1][2]
Totient launched from stealth mode in April 2021, announcing its AI-driven platform alongside a COVID-19 antibody program and $10 million in seed funding.[1] While specific founders are not detailed in available records, the company's inception centered on innovative use of tertiary lymphoid structures (TLSs)—naturally occurring immune hubs in tissues—to pinpoint antigens overlooked by traditional methods.[1][2] This marked a pivotal moment, positioning Totient at the intersection of AI and immunology during the height of the pandemic, with rapid validation through its debut funding and therapeutic pipeline.[1]
Totient stood out in biotech through these key strengths:
Totient rode the wave of AI-biotech convergence, a trend exploding in the early 2020s as machine learning decoded complex biological data faster than human-led research.[1] Its timing was ideal amid the COVID-19 crisis, when demand for rapid antigen discovery spiked, aligning with market forces like surging VC interest in AI drug platforms (e.g., seed funding secured at launch).[1] By spotlighting TLSs—a underutilized immune feature—Totient influenced the ecosystem, inspiring precision oncology and immunotherapy advances, even if its direct impact was short-lived amid high biotech attrition rates.[1][2]
With records framing Totient in the past tense, it likely wound down post-2021, a common fate for early-stage biotechs facing clinical hurdles.[2] Looking ahead, its TLS-AI approach could resurface through acquired IP or alumni ventures, shaped by ongoing trends like multimodal AI in immunology and personalized medicine. Totient's brief arc underscores AI's power to unearth hidden biology, priming the field for successors tackling tissue-specific therapies with greater staying power—echoing its stealth debut as a bold bet on immune-inspired innovation.[1][2]